Domestic researchers have found for the first time in the world that immuno-cancer drugs atetzolizumab plus bevacizumab ...

A new study has established that the follow-up of the fatty liver index (FLI), both baseline and longitudinally, is an ...

Over 80% of hepatocellular carcinoma (HCC) – the third-leading cause of cancer deaths globally – emerges from advanced liver fibrosis or cirrhosis. A comprehensive review in Hepatology International ...

Espervita Therapeutics, a biotechnology company developing targeted metabolic reprogramming therapies, announced the publication in Nature featuring groundbreaking preclinical data for the treatment ...

A new exploratory analysis of the HIMALAYA phase III trial involving patients with unresectable hepatocellular carcinoma ...

The American Cancer Society estimates that 41,210 people in the United States will be diagnosed with liver cancer in 2023. Many of these liver cancers will be hepatocellular carcinoma.

Hepatitis B vaccination stands as a powerful tool against liver cancer, particularly hepatocellular carcinoma, by preventing ...

This review explores the dynamic landscape of hepatocellular carcinoma (HCC) treatment, emphasizing on recent developments across various stages and therapeutic approaches. Although curative ...

Liver cancer is the most rapidly increasing cancer in the United States and is associated with a high cancer-related mortality. 1 Seventy-five percent of liver cancers are hepatocellular carcinoma ...

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the fourth most common cause of cancer-related death worldwide. 1 In 2017, there were an estimated 953,000 incident cases of liver ...